Non-Hodgkin's lymphoma survival rates double in England PharmaTimes This improved outlook for patients with NHL - the sixth most common cancer in the UK - is down to the emergence of new and more effective treatments, particularly rituximab (Roche's Rituxan), as well as better diagnosis leading to earlier detection of ... |
